Randomized Trial of Peginterferon alfa-2b and Ribavirin for 48 or 72 Weeks in Patients with Hepatitis C Virus Genotype 1 and Slow Virologic Response

Näytä kaikki kuvailutiedot



Pysyväisosoite

http://hdl.handle.net/10138/252447

Lähdeviite

SUCCESS Study Investigators & Färkkilä , M 2010 , ' Randomized Trial of Peginterferon alfa-2b and Ribavirin for 48 or 72 Weeks in Patients with Hepatitis C Virus Genotype 1 and Slow Virologic Response ' , Hepatology , vol. 52 , no. 4 , pp. 1201-1207 . https://doi.org/10.1002/hep.23816

Julkaisun nimi: Randomized Trial of Peginterferon alfa-2b and Ribavirin for 48 or 72 Weeks in Patients with Hepatitis C Virus Genotype 1 and Slow Virologic Response
Tekijä: SUCCESS Study Investigators; Färkkilä, Martti
Tekijän organisaatio: Department of Medicine
Clinicum
Päiväys: 2010-10
Kieli: eng
Sivumäärä: 7
Kuuluu julkaisusarjaan: Hepatology
ISSN: 0270-9139
DOI-tunniste: https://doi.org/10.1002/hep.23816
URI: http://hdl.handle.net/10138/252447
Tiivistelmä: The benefit of extending treatment duration with peginterferon (PEG-IFN) and ribavirin (RI3V) from 48 weeks to 72 weeks for patients with chronic hepatitis C genotype 1 infection has not been well established. In this prospective, international, open-label, randomized, multicenter study, 1,428 treatment-nave patients from 133 centers were treated with PEG-IFN alfa-26 (1.5 mu g/kg/week) plus RBV (800-1,400 mg/day). Patients with detectable hepatii is C virus (HCV) RNA and a >= 2-logio drop in IICV RNA levels at week 12 (slow responders) were randomized 1:1 to receive 48 weeks (n = 86) or 72 weeks (n = 73) of treatment. Sustained virologic response (SVR) rates were 43% in slow responders treated for 48 weeks and 48% in slow responders treated for 72 weeks (P = 0.644). Relapse rates were similar in slow responders treated for 48 or 72 weeks (47% versus 33%, P = 0.169). The safety profile was similar in both treatment arms; serious adverse events leading to discontinuation of treatment were observed in 3.5% of slow responders treated for 48 weeks and 8.2% of those treated for 72 weeks. Among slow responders with a
Avainsanat: PLUS RIBAVIRIN
TREATMENT DURATION
COMBINATION THERAPY
INFECTION
3121 General medicine, internal medicine and other clinical medicine
Vertaisarvioitu: Kyllä
Pääsyrajoitteet: openAccess
Rinnakkaistallennettu versio: publishedVersion


Tiedostot

Latausmäärä yhteensä: Ladataan...

Tiedosto(t) Koko Formaatti Näytä
Buti_et_al_2010_Hepatology.pdf 196.8KB PDF Avaa tiedosto

Viite kuuluu kokoelmiin:

Näytä kaikki kuvailutiedot